Supernus Pharmaceuticals, Inc.
$2.40B- Market cap
- $2.49B
- Debt
- +$43.80M
- Cash
- −$128.45M
Capital structure 98% equity / 2% debt · EV / Revenue 3.34x · EV / EBITDA 49.63x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SUPN stock price vs CDE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CDE's multiple
Needs CDE P/S.
Implied fair value · at SUPN's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SUPN FY 2025 (ended Dec 31, 2025) · CDE FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 3.34x · EV / EBITDA 49.63x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
COEUR MINING, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.04x
0.01x
Net debt / EBITDA
Leverage against operating earnings
-1.75x
-0.75x
Cash and equivalents
Liquid reserves on the balance sheet
$128.45M
$553.60M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
SUPN vs JAZZ
INCYTE CORP
SUPN vs INCY
ANI PHARMACEUTICALS INC
SUPN vs ANIP
Vanda Pharmaceuticals Inc.
SUPN vs VNDA
Harmony Biosciences Holdings, Inc.
SUPN vs HRMY
NEWMONT Corp /DE/
SUPN vs NEM
BARRICK GOLD CORP
SUPN vs GOLD
AGNICO EAGLE MINES LTD
SUPN vs AEM
HECLA MINING CO/DE/
SUPN vs HL
ROYAL GOLD INC
SUPN vs RGLD
$43.80M
$17.00M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.